TITLE

Cardiovascular side effects of inhaled salbutamol in hypoxic asthmatic patients

AUTHOR(S)
Burggraaf, J.; Westendorp, R. G. J.; int't Veen, J. C. C. M.; Schoemaker, R. C.; Sterk, P. J.; Cohen, A. F.; Blauw, G. J.; Westendorp, R G; in't Veen, J C
PUB. DATE
July 2001
SOURCE
Thorax;Jul2001, Vol. 56 Issue 7, p567
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
Background: Beta-2 adrenoceptor agonists have been associated with sudden death in asthma patients but the cause and underlying mechanism are unclear. Animal experiments indicate that the combination of hypoxia and beta2 agonists may result in detrimental cardiovascular effects. A study was undertaken to investigate the effect of hypoxia on the systemic vascular effects of salbutamol in patients with asthma who are hypoxic by assessing forearm blood flow (FBF) as a measure of peripheral vasodilatation. Methods: Eight men with mild asthma underwent the following treatments: normoxia + placebo (NP), normoxia + salbutamol (NS), hypoxia + placebo (HP), and hypoxia + salbutamol (HS). The period of mask breathing started at t=0 minutes, lasted for 60 minutes, and at 30 minutes 800 microg salbutamol was inhaled. The experiment was completed 30 minutes after the inhalation (t=60 minutes). For the hypoxia treatment the SpO2 level was 82%. Differences between treatments were sought using factorial ANOVA on percentage change from the pretreatment value. Results: There were no significant differences in blood pressure and potassium levels between the treatments. After 60 minutes the increase in FBF was 13% (95% CI -12 to 39) more for HP treatment than for NP, 21% (95% CI -5 to 46) more for NS than for NP, and 32% (95% CI 7 to 58) more for HS than for HP (p=0.016). The inhalation of salbutamol during hypoxia resulted in a significant increase in FBF of 45% (95% CI 20 to 71) compared with NP (p=0.001). Conclusion: Patients with asthma who are hypoxic and inhale beta2 agonists have serious systemic vascular side effects which may be an additional explanation for the association between asthma treatment and sudden death.
ACCESSION #
12915359

 

Related Articles

  • Long-Acting β2-Agonists in Asthma: Not so SMART? Currie, Graeme P.; Lee, Daniel K. C.; Lipworth, Brian J. // Drug Safety;2006, Vol. 29 Issue 8, p647 

    Asthma is a worldwide chronic disorder that is characterised by airway inflammation and hyper-responsiveness, which results in intermittent airflow obstruction and subsequent perception of symptoms and exacerbations. Inhaled corticosteroids are a fundamental component in the prevention of the...

  • Four in five asthma deaths may be due to long acting β agonists. Hagan, Pat // BMJ: British Medical Journal (International Edition);6/24/2006, Vol. 332 Issue 7556, p1467 

    The article discusses the results of a study which suggests that eighty per cent of asthma-related deaths in the United States may be due to long acting β agonists. Details of the study and its findings are provided. Long acting β agonists, such as salmeterol and formoterol, are examined.

  • Treatment of mild persistent asthma. Kaplan, Alan // Primary Care Respiratory Journal;Dec2008, Vol. 17 Issue 4, p251 

    There are several treatment options available for patients who have mild persistent asthma. After being shown a typical case study and three possible treatment options, three respiratory specialists each selected a different option. The options were: using a combination beclometasone/albuterol...

  • Management of asthma in children. Townshend, J.; Hails, S.; Mckean, M. // BMJ: British Medical Journal (International Edition);8/4/2007, Vol. 335 Issue 7613, p253 

    The article presents an overview of the management of asthma in children. A discussion of what the acute managemnt of asthma, long term management of atopic asthma and episodic viral wheeze is is presented. The benefits and disadvantages of the use of corticosteroids and long acting beta...

  • Maintenance plus as needed budesonide plus formoterol was better than fixed dose for severe exacerbations in asthma. O'byrrie, P. M.; Bisgaard, H.; Godard, P. P. // Evidence Based Medicine;Aug2005, Vol. 10 Issue 4, p116 

    The article presents a study on the effectiveness of budesonide plus formoterol (BUD+FORM) for severe exacerbations in asthma. Researchers found that time to first severe exacerbation was greater in the BUD+FORM for both group than in the BUD+FORM plus SABA group or BUD plus SABA group....

  • Maintenance plus as needed budesonide plus formoterol was better than fixed dose for severe exacerbations in asthma: Commentary. Rees, P. John // Evidence Based Medicine;Aug2005, Vol. 10 Issue 4, p116 

    Focuses on the control of asthma by inhaled long acting beta agonists and corticosteroids. Effectiveness of the combination of fluticasone/salmeterol and budesonide/formoterol; Dose response of corticosteroids and formoterol; Onset of bronchodilation.

  • Risks of long-acting beta-agonists in achieving asthma control. Bicescu, Gabriela // Maedica - a Journal of Clinical Medicine;2009, Vol. 4 Issue 2, p176 

    The article provides information on the risk of long-acting beta-agonist (LABAs) in the treatment of patients with asthma. It states that asthmatics who used LABAs have improved lung functions and diminished asthma symptoms. It adds that LABAs are well tolerated and have high efficacy in...

  • COMMENTARY. Ribas, J. // British Journal of Sports Medicine;Aor2006, Vol. 40 Issue 4, p366 

    The article comments on the paper "Use of β2 agonists in sport: are the present criteria right?," by J. Naranjo Orellana and colleagues in this issue. The findings show that the use of these drugs could provide the asthmatic athlete the chance of full breathing capacity without any extra...

  • Ultra-Long-Acting β2-Adrenoceptor Agonists: An Emerging Therapeutic Option for Asthma and COPD? Matera, Maria Gabriella; Cazzola, Mario // Drugs;2007, Vol. 67 Issue 4, p503 

    There has been a real interest recently in developing once-daily β2-adrenoceptor agonists (ultra-long-acting β2-adrenoceptor agonists [ultra-LABAs]) for treating asthma and chronic obstructive pulmonary disease (COPD) in an attempt to simplify their management, although an increasing...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics